← All stocks

TransMedics Group, Inc.

TMDX Net selling
CIK 0001756262 #1701 in the set updated 17 Sep 2026
Bought (120 mo)
$6.34M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$170.55M
$7.28M on a plan · $93.07M straight out of an exercise
Sold at will
$70.20M
85 of 410 sales
Net
−$164.21M
−$63.86M against sales at will

By person

22 insiders · 441 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Hassanein Waleed H
President & CEO
$2.98M (4)
$48.40M (96) scheduled
−$45.42M
666,102
1.92%
$54.37M
+80.5%
Khayal Tamer I
Chief Commercial Officer
$30.34M (127) scheduled
−$30.34M
36,042
0.1039%
$2.94M
−77.0%
ABRAMS CAPITAL MANAGEMENT, L.P. entity
10% owner
$28.53M (2)
−$28.53M
2,624,712
7.57%
$214.26M
Gordon Stephen
Chief Financial Officer
$16.94M (33) scheduled
−$16.94M
21,299
0.0614%
$1.74M
−78.7%
TOBIN JAMES R
Director
$14.29M (20)
−$14.29M
431,618
1.24%
$35.23M
−43.9%
UNITED THERAPEUTICS Corp entity
10% owner
$9.38M (1)
−$9.38M
2,053,240
5.92%
$167.61M
Basile Edward M
Director
$136.00K (1)
$6.35M (22) scheduled
−$6.21M
5,788
0.0167%
$472.47K
Carey John F
VP of Operations
$3.23M (64) scheduled
−$3.23M
14,120
0.0407%
$1.15M
+1,249%
Weill David
Director
$434.06K (3)
$3.47M (8) scheduled
−$3.03M
16,392
0.0473%
$1.34M
Kania Edwin
Director
$2.79M (3)
+$2.79M
1,186,694
3.42%
$96.87M
−38.6%
Corcoran Nicholas
See remarks
$2.59M (3) scheduled
−$2.59M
41,558
0.1198%
$3.39M
Ranganath Anil P.
See remarks
$1.40M (5) scheduled
−$1.40M
13,091
0.0378%
$1.07M
+6,512%
Hernandez Gerardo
Chief Financial Officer
$1.25M (4) scheduled
−$1.25M
31,935
0.0921%
$2.61M
Sullivan John F
VP of Quality & Engineering
$1.12M (8) scheduled
−$1.12M
14,273
0.0412%
$1.17M
−57.1%
Provost Miriam
VP, Global Regulatory Affairs
$1.09M (9) scheduled
−$1.09M
23,348
0.0673%
$1.91M
Lovell Stephanie
Director
$799.22K (4) scheduled
−$799.22K
5,788
0.0167%
$472.47K
Gunderson Thomas J.
Director
$722.38K (1) scheduled
−$722.38K
16,642
0.0480%
$1.36M
DAMME LAURA
VP, Clinical Affairs
$665.75K (3) scheduled
−$665.75K
5,685
0.0164%
$464.07K
Flagship Ventures Fund IV General Partner LLC entity
10% owner
2,650,870
7.64%
$216.39M
−43.0%
Cecere Giovanni
Chief Commercial Officer
19,057
0.0550%
$1.56M
+139.0%
Forsyth Matthew S.
See Remarks
15,409
0.0444%
$1.26M
RAINES MERILEE
Director
6,981
0.0201%
$569.86K
Insider
Date
Role
Action
Shares
Price
Amount
Weill David
11 Sep 2026
Director
Buy
1,336
$81.63
$109.06K
Hassanein Waleed H
17 Nov 2025
President & CEO
Buy indirect
8,775
$114.00
$1.00M
Hassanein Waleed H
7 Aug 2025
President & CEO
Buy indirect
1,858
$116.85
$217.11K
Hassanein Waleed H
7 Aug 2025
President & CEO
Buy indirect
6,617
$116.08
$768.10K
Hassanein Waleed H
6 Aug 2025
President & CEO
Buy indirect
8,400
$118.68
$996.91K
Weill David
29 Aug 2023
Director
Buy
2,500
$62.00
$155.00K
Showing 250 of 441 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 328
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 21
Sales straight out of an exercise 304
Sales at will 85
Transactions with no price 0
Shares from compensation/vesting 21,466,869
Sales filed before the plan box existed 46
History held since 6 May 2019